IRIS
FUMAROLA, Claudia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.045
EU - Europa 3.069
AS - Asia 2.878
SA - Sud America 476
AF - Africa 163
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.638
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.979
SG - Singapore 1.172
CN - Cina 990
IT - Italia 834
IE - Irlanda 431
FI - Finlandia 410
BR - Brasile 389
SE - Svezia 388
DE - Germania 285
HK - Hong Kong 215
VN - Vietnam 155
UA - Ucraina 133
NL - Olanda 109
GB - Regno Unito 100
ZA - Sudafrica 93
IN - India 84
TR - Turchia 80
RU - Federazione Russa 78
FR - Francia 76
AT - Austria 54
BE - Belgio 49
CA - Canada 44
CI - Costa d'Avorio 40
AR - Argentina 36
PL - Polonia 30
ES - Italia 23
ID - Indonesia 23
BD - Bangladesh 22
KR - Corea 22
CZ - Repubblica Ceca 20
EC - Ecuador 16
JP - Giappone 16
IQ - Iraq 15
MX - Messico 14
PK - Pakistan 13
CO - Colombia 12
PS - Palestinian Territory 10
IR - Iran 9
LT - Lituania 9
MA - Marocco 8
VE - Venezuela 8
UZ - Uzbekistan 7
LU - Lussemburgo 6
EG - Egitto 5
HU - Ungheria 5
KG - Kirghizistan 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
AL - Albania 4
JO - Giordania 4
KE - Kenya 4
LB - Libano 4
NP - Nepal 4
NZ - Nuova Zelanda 4
PT - Portogallo 4
TN - Tunisia 4
AZ - Azerbaigian 3
CH - Svizzera 3
MD - Moldavia 3
PE - Perù 3
QA - Qatar 3
RO - Romania 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AO - Angola 2
BO - Bolivia 2
CL - Cile 2
CY - Cipro 2
EE - Estonia 2
JM - Giamaica 2
KZ - Kazakistan 2
MY - Malesia 2
NO - Norvegia 2
PA - Panama 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AM - Armenia 1
AU - Australia 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
NI - Nicaragua 1
OM - Oman 1
RS - Serbia 1
SA - Arabia Saudita 1
SI - Slovenia 1
TJ - Tagikistan 1
Totale 10.635
Salva come PNG Salva come JPEG
Città #
Dallas 627
Singapore 620
Dublin 431
Ashburn 393
Chandler 392
Ann Arbor 338
Santa Clara 273
Parma 267
Beijing 222
Hong Kong 213
Dearborn 155
Jacksonville 144
Boardman 131
New York 115
Shanghai 97
Los Angeles 93
Munich 92
Hefei 88
Johannesburg 88
Nanjing 84
Milan 70
Princeton 67
Izmir 65
Bremen 60
Helsinki 49
Ho Chi Minh City 46
Vienna 46
Nanchang 41
Abidjan 40
Chicago 40
San Mateo 40
São Paulo 39
Shenyang 37
Moscow 34
Wilmington 34
Brussels 31
Buffalo 31
Modena 30
Hanoi 29
Kunming 28
Bologna 27
Columbus 27
Hebei 27
Jinan 24
The Dalles 24
Marseille 23
Seattle 23
Tianjin 23
Warsaw 23
Des Moines 22
Seoul 21
Jakarta 20
London 20
Redmond 20
Turku 20
Council Bluffs 18
Toronto 18
Nuremberg 17
Woodbridge 17
Denver 16
Frankfurt am Main 15
Pune 15
Amsterdam 14
Manchester 14
Norwalk 14
Phoenix 14
Reggio Emilia 14
Stockholm 14
Tokyo 14
Changsha 13
Chennai 13
Guangzhou 13
Poplar 13
Rio de Janeiro 13
Brescia 12
Jiaxing 12
Neviano degli Arduini 12
Rome 12
Wayne 12
Bari 11
Leawood 11
Montreal 11
Boston 10
Florence 10
Fremont 10
Houston 10
Zhengzhou 10
Brasília 9
Gaza 9
Haiphong 9
Augusta 8
Bengaluru 8
Brooklyn 8
Dong Ket 8
Fuzhou 8
Grafing 8
Orem 8
Verona 8
Ardabil 7
Binche 7
Totale 6.591
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 310
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 219
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 206
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 204
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 201
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 184
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 180
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 179
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 171
Novel activity of a synthetic decapeptide against Toxoplasma gondii Tachyzoites 170
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 169
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 164
Characterization of gefitinib uptake in NSCLC cell lines 163
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 163
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 163
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 162
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 158
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 155
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 155
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 151
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 151
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 149
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 148
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 148
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 147
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 147
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 147
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 146
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 146
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 144
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 144
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 144
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 140
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 137
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 136
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 135
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 135
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 134
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 134
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 133
Physico-chemical characterization and biological evaluation of two fibroin materials 130
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 130
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 128
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 128
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 128
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 124
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 119
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 117
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 115
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 114
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 113
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 112
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 111
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 111
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation 110
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 109
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 106
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 103
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 102
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 101
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 99
Immunotherapeutic approaches in malignant pleural mesothelioma 97
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways 94
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 92
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines 91
Effect of inducible FHIT and p53 expression on CALU-1 cell proliferation. 89
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 88
Effect of letrozole and sorafenib on cell proliferation and apoptosis of MCF-7/AROM-1 breast cancer cell line 87
Synergistic activity of letrozole and sorafenib on breast cancer cells 86
Increased level of inducible HSP70 in cells exposed to electromagnetic fields. 86
Synergic anti-proliferative effect of gefitinib and RAD001 in non small cell lung cancer cell lines 86
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary 83
Targeting FGFR1 pathway in squamous cell lung cancer 83
Erlotinib potentiates Cetuximab-dependent call citotoxicity in EGFR wild type NSCLC cell lines 83
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer 82
Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" 82
Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer 81
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 76
Evaluation of gefitinib maintenance in an EGFR-mutant NSCL cell line with acquired resistance 73
New therapeutic strategies for malignant pleural mesothelioma 73
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 67
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 66
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 57
Effect of constitutive expression of the fragile histidine triad gene on non small cell lung cancer 47
Correction to: The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells (Journal of Experimental & Clinical Cancer Research, (2018), 37, 1, (72), 10.1186/s13046-018-0741-3) 38
null 31
Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling 13
Totale 10.813
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.429
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.429
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021356 0 0 0 0 0 16 48 30 86 23 113 40
2021/2022418 36 15 21 38 15 10 70 30 21 19 30 113
2022/20231.685 147 178 118 107 158 192 14 141 527 9 73 21
2023/2024800 38 49 28 43 54 156 67 68 33 45 89 130
2024/20252.438 87 110 167 178 249 259 177 124 283 199 205 400
2025/20263.064 427 480 797 537 721 102 0 0 0 0 0 0
Totale 10.813